Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB Plus MenACWY Formulations

NCT01210885 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01210885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01210885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB Plus MenACWY Formulations
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
July 31, 2011
Enrollment
495 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis